Shares of HIVE Blockchain Technologies Ltd. (CVE:HIV – Get Free Report) have been given a consensus recommendation of “Strong Buy” by the five research firms that are presently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a strong buy recommendation.
HIV has been the topic of several recent research reports. Roth Capital upgraded HIVE Blockchain Technologies to a “strong-buy” rating in a report on Wednesday, December 18th. Keefe, Bruyette & Woods upgraded HIVE Blockchain Technologies to a “moderate buy” rating in a research note on Wednesday, January 8th. Finally, Rosenblatt Securities raised HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Friday, March 7th.
View Our Latest Stock Analysis on HIV
HIVE Blockchain Technologies Stock Performance
HIVE Blockchain Technologies Ltd. is a services company in the Business Services industry.
Further Reading
- Five stocks we like better than HIVE Blockchain Technologies
- How to Invest in Biotech Stocks
- Can TikTok Stock Picks Really Make You Rich?
- Which Wall Street Analysts are the Most Accurate?
- The “Quality” Rotation: Back to Basics Investing
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
